Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Devices Expand Their Role in Retinal Disease

Executive Summary

Four years following FDA approval, Lucentis remains the standard of care for the treatment of neovascular (wet) age-related macular degeneration (AMD) and has been widely adopted for off-label treatment of other retinal diseases. Companies are pursuing new drugs that may have more favorable dosing profiles, device-based technologies that may reduce the dosing frequency of Lucentis, and implantable drug delivery vehicles designed to deliver drugs to the back of the eye that may be applicable to a broad range of retinal therapies.

You may also be interested in...



Medical Device Market & Industry Briefs, August 2012

Brief summaries of recent medtech market and industry developments. This month we cover continuing pressures on the DES and ICD markets, update Edwards’ efforts to roll out its Sapien device for TAVR, and report on QLT’s decision to sell its punctal plug technology.

AAO Highlights: Back (of the Eye) to the Future

The 2009 meeting of the American Academy of Ophthalmology showcased the latest developments in cataract/refractive surgery, glaucoma, retina, and other ophthalmic subspecialties. The cataract/refractive surgery market has been under significant economic pressure recently due to a recessionary drop in elective ophthalmic procedures. However, evolving treatments for "back of the eye" conditions, such as age-related macular degeneration (AMD) and diabetic retinopathy, are making significant inroads toward improved patient outcomes for these common and devastating diseases and continue to energize the retina products market.

Finance Watch: Karuna, Cerevel And Others Benefit From Improving Biotech Sentiment

Good news in the biopharma industry and the US economy gave public drug developers the boost they needed to raise cash, including Karuna’s $750m offering. Private company financings slowed during the second week of August, but Prellis and Vector BioPharma raised venture capital.

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

MT035398

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel